Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma
esmo - Findings from the ZSAB-neoGOLP study
AI Summary: The ZSAB‑neoGOLP trial shows that giving a four‑drug neoadjuvant regimen—gemcitabine, oxaliplatin, lenvatinib and toripalimab—before surgery prolongs event‑free survival for patients with resectable, high‑risk intrahepatic cholangiocarcinoma. The finding suggests preoperative systemic therapy can downstage aggressive tumors and delay recurrence, potentially changing treatment sequencing for this challenging disease.
NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
oncodaily - A major international clinical trial, NRG-LU005, has provided important new insight into how immunotherapy should be used in limited-stage small cell lung cancer (SCLC). While immune checkpoint inhibitors have significantly […]
AI Summary: A major international trial tested whether adding the PD‑L1 inhibitor atezolizumab to concurrent chemoradiotherapy for limited‑stage small‑cell lung cancer would boost outcomes. The study found no significant survival benefit, prompting clinicians to rethink the timing and role of immune checkpoint blockade in curative‑intent SCLC rather than assuming more drugs always means better results.
A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices
medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…
AI Summary: Researchers have identified HORMAD1, a normally reproductive‑cell gene, as a vulnerability in some triple‑negative breast cancers. Preclinical work suggests exploiting this target could guide patient selection and novel therapies, opening a promising — if early‑stage — route for a tumor type that desperately needs smarter options.
- HORMAD1: reproductive gene reveals vulnerability in triple‑negative breast cancer (3)
- New insights into why aggressive breast cancers grow and spread (3)
- OTHER: related cancer research and approvals outside this TNBC angle (5)
- All Other Stories
HORMAD1: reproductive gene reveals vulnerability in triple‑negative breast cancer
New insights into why aggressive breast cancers grow and spread
OTHER: related cancer research and approvals outside this TNBC angle
All Other Stories
Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision
Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…
AI Summary: GSK has licensed its investigational drug linerixibat to Alfasigma for $300 million upfront, transferring global rights as the therapy nears regulatory decisions for cholestatic liver itch. The deal accelerates Alfasigma’s rare-disease ambitions while allowing GSK to reposition its pipeline — a tidy corporate shuffle with real implications for patients with debilitating pruritus.
Roche’s big hope breast cancer drug fails in crucial first-line trial
Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...
AI Summary: Roche’s experimental breast cancer oral agent failed to meet its primary endpoint in a pivotal first‑line trial, dashing expectations that it would become a major new therapy. The negative readout forces a strategic rethink for the program and raises questions about near‑term prospects for what had been touted as a potential blockbuster.
Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia
oncodaily - Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, […]
AI Summary: A global phase 3 trial shows romiplostim markedly reduces chemotherapy‑induced thrombocytopenia, cutting severe low‑platelet events and helping patients stay on planned treatment schedules. The finding promises to lower bleeding risk and avoid dose delays, a relief for clinicians and patients alike — and for anyone tired of rescheduled infusions.
Grail names new CEO as Bob Ragusa retires
Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...
AI Summary: Grail announced a leadership transition as long‑time chief executive Bob Ragusa retires and hands operational control to current president Josh Ofman. The move marks a new chapter for the cancer‑screening company as stakeholders watch for strategic shifts and commentary about the company’s unusual corporate journey and future direction.
Ipsen pulls cancer drug Tazverik from market over safety risks
Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...
AI Summary: Ipsen has removed its EZH2 inhibitor Tazverik (tazemetostat) from the U.S. market after safety issues flagged by an independent monitoring review. The withdrawal forces clinicians to pivot to alternative therapies and triggers regulatory and clinical re‑examination of the drug’s benefit‑risk profile for patients previously depending on it.
FDA Transparency Push Expands to Monitoring Safety of Vaccines and Other Regulated Products
Frank Vinluan / medcitynews - The FDA said consolidating safety reporting into a single platform, the Adverse Event Monitoring System (AEMS), will increase transparency and reduce costs. But like the legacy systems it replaces, AEMS reports are unverified so causation and frequency of…
AI Summary: The FDA is consolidating multiple safety reporting systems into a single public Adverse Event Monitoring System to centralize reports for drugs, biologics, vaccines, cosmetics and animal products. The move aims to improve transparency, reduce fragmented reporting, and streamline monitoring — a tidy solution if it works as promised.
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors
Torahito A. Gao, Ryan M. Shih, Justin D. Clubb, Shao-Hsi Hung, Tanya Singh, Laura B. James-Allan, Ga / science - Science Translational Medicine, Volume 18, Issue 839, March 2026.
AI Summary: Researchers engineered CAR‑T cells to secrete VEGF‑neutralizing single‑chain antibodies, improving infiltration and antitumor activity against solid tumors in preclinical models. By locally neutralizing VEGF, the approach remodels the tumor microenvironment and enhances CAR‑T efficacy, offering a plausible strategy to overcome the long‑standing barrier of poor CAR‑T performance in solid cancers.
Elizabeth McKenna: New Cancer Grand Challenges Teams Announced
oncodaily - Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: “The new Cancer Grand Challenges teams have just been announced! Read about the teams tackling cancer avoidance, mechanisms […]
AI Summary: Global funders announced new Cancer Grand Challenges awards, backing five international teams with large, high‑risk grants to pursue transformative cancer science. The initiative aims to accelerate unconventional, high‑reward projects and foster cross‑disciplinary collaboration — essentially underwriting audacity in hopes that at least one risky bet pays off.
ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS
oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]
AI Summary: At ASCO GU, investigators showcased belzutifan‑based combinations for renal cell carcinoma, including belzutifan with lenvatinib and perioperative belzutifan plus pembrolizumab. Data presented indicate these HIF‑2α‑targeted regimens can extend disease‑free intervals in high‑risk clear‑cell RCC, prompting interest in integrating hypoxia‑axis inhibitors into multimodal kidney‑cancer care.
New FDA bonus pilot to address 'workforce challenges'
Max Bayer / endpoints - A new bonus pilot program meant to reward fast-working FDA reviewers will be funded in part by money from industry user fees, the first details on how Commissioner Marty Makary plans to finance the incentive ...
AI Summary: The FDA has introduced a pilot program offering performance bonuses to expedite regulatory reviews, aiming to tackle reviewer workload and improve timeliness. Funded partly by industry user fees, the initiative seeks to reward faster, high‑quality reviews while balancing independence and efficiency—proof that carrots sometimes replace the endless stick of overtime.
New AI tool predicts best pancreatic cancer treatment
medicalxpress - A new tool co-developed by investigators from Cedars-Sinai Health Sciences University can predict which of two available chemotherapy options for pancreatic cancer would be more effective for an individual patient.
AI Summary: A Cedars‑Sinai–developed AI platform predicts which of two standard chemotherapy regimens will best suit individual pancreatic cancer patients. The model analyzes clinical and molecular data to guide therapy selection, aiming to personalize treatment and improve outcomes in a disease notorious for poor prognosis—because guesswork is overrated when lives are at stake.
FDA lifts hold on Intellia trial
Ella Jeffries / beckershospitalreview - The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver transaminase elevations and elevated bilirubin following a Sept. 3…
AI Summary: The FDA has lifted clinical holds on Intellia Therapeutics’ Phase 3 gene‑editing trials, allowing the company to resume patient enrollment and advance its nexiguran (nex‑z) development program. Regulators appear satisfied with submitted safety updates, clearing a major regulatory hurdle and moving the gene-editing program back toward its clinical milestones.
Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology
Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…
AI Summary: Moderna has agreed to settle long-running patent disputes over its COVID-19 vaccine technology for up to $2.25 billion, resolving litigation with several claimants. The deal provides Moderna with broad licensing rights and clears a major legal uncertainty, allowing the company to move forward without another courtroom cliffhanger.
Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…
AI Summary: Servier is buying Day One Biopharmaceuticals for about $2.5 billion to bolster its rare oncology portfolio, gaining access to promising targeted therapies. The deal expands Servier’s presence in specialty cancer medicines and aligns with its strategic push into rare tumors, with integration and regulatory steps expected to follow.
FDA vaccine chief to step down in April
Ella Jeffries / beckershospitalreview - Vinay Prasad, MD, the FDA’s top regulator of vaccines and cell and gene therapies, will step down at the end of April, an agency spokesperson confirmed to Becker’s. Dr. Prasad joined the agency in 2025 on a one-year sabbatical from the University of Calif…
AI Summary: Vinay Prasad, the FDA’s top regulator for vaccines and cell and gene therapies, will step down at the end of April amid mounting criticism over controversial decisions that reportedly overrode agency scientists and spooked stakeholders. His exit follows prolonged internal and external disputes about regulatory judgment and leadership style.
AI blood test finds silent liver disease years before symptoms
sciencedaily - Researchers created an AI-driven liquid biopsy that scans patterns in fragments of DNA circulating in the blood. The system detected early liver fibrosis and cirrhosis—conditions that often go unnoticed until serious damage occurs. By analyzing genome-wid…
AI Summary: Researchers unveiled an AI‑driven liquid biopsy that scans genome‑wide cell‑free DNA fragment patterns to flag liver fibrosis, cirrhosis and chronic liver disease well before symptoms appear. Early results indicate the test can identify disease signals years ahead of clinical diagnosis, offering a shot at much earlier intervention — if practice and payers cooperate.
Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy
livescience - An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.
AI Summary: An experimental treatment markedly cut seizures and eased symptoms in children with Dravet syndrome, offering families dramatic improvements where few options existed. Early clinical data show promising safety and efficacy signals, but researchers caution larger, longer trials and regulatory review are needed before this becomes a routine option.